sterna biologicals GmbH & Co. KG

Sterna Biologicals GmbH & Co. KG is a clinical-stage immunology company developing novel, first-in-class, safe and efficient GATA-3-specific broad-spectrum immunomodulating therapies for millions of patients suffering from type 2 inflammation driven chronic diseases. By targeting GATA-3, a key transcription factor that plays a central role in these diseases, the company’s proprietary DNAzyme based drug candidate hgd40 broadly antagonizes several inflammatory processes and mediators at the same time.

Sterna has successfully completed four Phase IIa clinical trials and is progressing towards advanced mid-stage clinical development in the company’s lead indications asthma and ulcerative colitis.

 

 

 


Sterna Biologicals at a glance:

 

Field of Activity
Development of novel, first-in-class antisense oligonucleotide-based broad-spectrum treatments for chronic inflammatory diseases; tackling Type 2 inflammation by targeting master transcription factor GATA-3 with DNAzymes, a special type of antisense.
Ownership Structure and Financing Privately held. Investors include Engelhard Arzneimittel and UBG Unternehmensberatung & Betreuung.
Products/Services sterna’s lead programs in asthma (SB010) and ulcerative colitis (SB012) both leverage the company‘s proprietary and patent protected active pharmaceutical ingredient hgd40.

SB010 in asthma: Inhaled liquid formulation which has showed solid safety data and strong efficacy signals in mild asthmatics. The company is preparing a phase IIa study in patients with moderate to severe asthma.

SB012 in ulcerative colitis: Enema formulation which has led to marked clinical and endoscopic improvements in a phase II a trial with severe UC patients. Currently, the company is developing an oral formulation to be used in the planned phase IIb trial.

Additionally, sterna has a pipeline of further GATA-3 antagonist development programs in COPD and atopic dermatitis.

Unique selling point By targeting GATA-3, sterna‘s proprietary DNAzyme hgd40 broadly antagonizes several inflammatory processes and mediators at the same time – opposite to many existing treatments. With this innovative approach, sterna is the only company that has successfully made GATA-3 druggable and demonstrated that GATA-3 downregulation could provide for a truly novel, first-in-class, broad-spectrum,
non-steroidal anti-inflammatory therapy.
Date of Incorporation/
Number of Employees
2006/10

 

Contact:

Christian Pangratz, CEO

 

Address Bismarckstrasse 7
35037 Marburg
Telephone/Telefax +49 6421 98300-50/-599
E-mail info@sterna-biologicals.com
Web Address www.sterna-biologicals.com
Social Media LinkedIn